Biocryst Pharmaceuticals (BCRX) Non Operating Interest Expenses (2011 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Non Operating Interest Expenses for 16 consecutive years, with $21.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 0.6% year-over-year to $21.7 million; the trailing twelve-month figure through Jun 2026 stood at $75.3 million (down 20.21% YoY), and the FY2025 full-year result was $78.9 million, down 19.94% from the prior year.
• Non Operating Interest Expenses climbed to $21.7 million in Q2 2026 per BCRX's latest filing, from $19.8 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $28.9 million in Q2 2023 and bottomed at $14.1 million in Q4 2025.
• Historically, Non Operating Interest Expenses has averaged $23.7 million across 5 years, with a median of $24.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non Operating Interest Expenses jumped 84.73% in 2022, then slumped 42.19% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $26.5 million in 2022, then dropped by 7.09% to $24.6 million in 2023, then fell by 0.55% to $24.4 million in 2024, then plunged by 42.19% to $14.1 million in 2025, then surged by 53.6% to $21.7 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $21.7 million, $19.8 million, and $14.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.